First-in-Human Dose-Escalation Study of Cyclin-Dependent Kinase 9 Inhibitor VIP152 in Patients with Advanced Malignancies Shows Early Signs of Clinical Efficacy

• Published in: Clinical cancer research 2022-04, Vol.28 (7), p.1285-1293
• Main Authors: Diamond, Jennifer R, Boni, Valentina, Lim, Emerson, Nowakowski, Grzegorz, Cordoba, Raul, Morillo, Daniel, Valencia, Ray, Genvresse, Isabelle, Merz, Claudia, Boix, Oliver, Frigault, Melanie M, Greer, Joy M, Hamdy, Ahmed M, Huang, Xin, Izumi, Raquel, Wong, Harvey, Moreno, Victor
• Format: Article
• Language: English
• Subjects: Adult; Cyclin-Dependent Kinase 9; Dose-Response Relationship, Drug; Humans; Maximum Tolerated Dose; Neoplasms - drug therapy; Neoplasms - metabolism; Neutropenia; Protein Kinase Inhibitors - adverse effects; Treatment Outcome
• ISSN: 1078-0432; 1557-3265
• DOI: 10.1158/1078-0432.CCR-21-3617

To report on the first-in-human phase I study of VIP152 (NCT02635672), a potent and highly selective cyclin-dependent kinase 9 (CDK9) inhibitor. Adults with solid tumors or aggressive non-Hodgkin lymphoma who were refractory to or had exhausted all available therapies received VIP152 monotherapy as a 30-minute intravenous, once-weekly infusion, as escalating doses (5, 10, 15, 22.5, or 30 mg in 21-day cycles) until the MTD was determined. Thirty-seven patients received ≥ 1 VIP152 dose, with 30 mg identified as the MTD based on dose-limiting toxicity of grade 3/4 neutropenia. The most common adverse events were nausea and vomiting (75.7% and 56.8%, respectively), all of grade 1/2 severity. Of the most common events, grade 3/4 events occurring in > 1 patient were neutropenia (22%), anemia (11%), abdominal pain (8%), increased alkaline phosphatase (8%), and hyponatremia (8%). Day 1 exposure for the MTD exceeded the predicted minimum therapeutic exposure and reproducibly achieved maximal pathway modulation; no accumulation occurred after multiple doses. Seven of 30 patients with solid tumors had stable disease (including 9.5 and 16.8 months in individual patients with pancreatic cancer and salivary gland cancer, respectively), and 2 of 7 patients with high-grade B-cell lymphoma with MYC and BCL2/BCL6 translocations (HGL) achieved durable complete metabolic remission (ongoing at study discontinuation, after 3.7 and 2.3 years of treatment). VIP152 monotherapy, administered intravenously once weekly, demonstrated a favorable safety profile and evidence of clinical benefit in patients with advanced HGL and solid tumors.